BioRestorative Therapies Inc
BioRestorative Therapies Inc (BRTX) is a microcap company operating in the regenerative medicine / biotechnology space. With a market capitalisation of about $13.8m, it is small and typically considered speculative. Investors should know the business may be development‑stage with limited or variable revenue, and value drivers tend to be clinical progress, regulatory milestones and partnerships rather than steady earnings. Shares can be illiquid and subject to wide price swings; there is a material risk of dilution if the company raises capital. Time horizons for drug or device development are long and outcomes uncertain, so potential upside comes with significant downside risk. This summary is for general educational purposes only and not personalised investment advice — consider your risk tolerance, conduct further research and, if needed, consult a financial adviser before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioRestorative Therapies' stock with a target price of $11.5, indicating strong growth potential.
Financial Health
BioRestorative Therapies is showing strong profitability and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BRTX
3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Regenerative focus
The company works in regenerative medicine where clinical milestones can drive value — though outcomes and timelines are uncertain.
Microcap volatility
With a market cap around $13.8m, shares may be illiquid and prone to large swings; expect higher risk and potential dilution.
Clinical and funding timing
Progress often depends on trials, approvals and partnerships, meaning cash needs and long timelines; performance can vary considerably.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
